Zanubrutinib for the Treatment of B-cell Malignancies
Allison Rosenthal, Javier Munoz
touchREVIEWS in Oncology & Haematology. 2022;18(1):44–52 DOI: https://doi.org/10.17925/OHR.2022.18.1.44
B-cell signalling pathways are critical regulators of B-cell development, expansion, and survival and function via various mediators, including Src family kinases (SFKs), spleen tyrosine kinase, Bruton’s tyrosine kinase (BTK) and phosphatidylinositol 3 kinase (PI3K) (Figure 1).1,2 BTK, a member of the Tec protein tyrosine kinase (TEC) family, is overexpressed in many B-cell leukaemias and lymphomas, and […]